Rhythm Pharmaceuticals (RYTM) Competitors

$90.78 +1.14 (+1.27%)

Closing price 04:00 PM Eastern

Extended Trading

$90.80 +0.02 (+0.02%)

As of 05:26 PM Eastern

RYTM vs. ROIV, INSM, INCY, BNTX, and GMAB

Should you buy Rhythm Pharmaceuticals stock or one of its competitors? Rhythm Pharmaceuticals's main competitors and comparable companies include Roivant Sciences (ROIV), Insmed (INSM), Incyte (INCY), BioNTech (BNTX), and Genmab A/S (GMAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rhythm Pharmaceuticals compare to Roivant Sciences?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Rhythm Pharmaceuticals presently has a consensus target price of $140.89, indicating a potential upside of 57.17%. Roivant Sciences has a consensus target price of $45.64, indicating a potential upside of 33.40%. Given Rhythm Pharmaceuticals' higher possible upside, equities research analysts plainly believe Rhythm Pharmaceuticals is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

In the previous week, Roivant Sciences had 12 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 12 mentions for Roivant Sciences and 0 mentions for Rhythm Pharmaceuticals. Roivant Sciences' average media sentiment score of 0.64 beat Rhythm Pharmaceuticals' score of 0.00 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Rhythm Pharmaceuticals	Neutral
Roivant Sciences	Positive

64.8% of Roivant Sciences shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 8.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Rhythm Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$239.92M	25.61	-$196.54M	-$3.11	N/A
Roivant Sciences	$8.26M	2,991.59	-$299.77M	-$0.53	N/A

Rhythm Pharmaceuticals has a beta of 2.01, meaning that its stock price is 101% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

Rhythm Pharmaceuticals has a net margin of -85.59% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

Summary

Roivant Sciences beats Rhythm Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to Insmed?

Insmed (NASDAQ:INSM) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Insmed has a net margin of -76.94% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Insmed's return on equity of -123.94% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

In the previous week, Insmed had 12 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 12 mentions for Insmed and 0 mentions for Rhythm Pharmaceuticals. Insmed's average media sentiment score of 0.05 beat Rhythm Pharmaceuticals' score of 0.00 indicating that Insmed is being referred to more favorably in the media.

Company	Overall Sentiment
Insmed	Neutral
Rhythm Pharmaceuticals	Neutral

Rhythm Pharmaceuticals has lower revenue, but higher earnings than Insmed. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	36.18	-$1.28B	-$4.11	N/A
Rhythm Pharmaceuticals	$239.92M	25.61	-$196.54M	-$3.11	N/A

Insmed currently has a consensus price target of $200.57, indicating a potential upside of 99.61%. Rhythm Pharmaceuticals has a consensus price target of $140.89, indicating a potential upside of 57.17%. Given Insmed's stronger consensus rating and higher possible upside, equities research analysts clearly believe Insmed is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76

Insmed has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 2.01, meaning that its share price is 101% more volatile than the broader market.

Summary

Insmed beats Rhythm Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to Incyte?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Rhythm Pharmaceuticals has a beta of 2.01, suggesting that its share price is 101% more volatile than the broader market. Comparatively, Incyte has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Rhythm Pharmaceuticals currently has a consensus target price of $140.89, indicating a potential upside of 57.17%. Incyte has a consensus target price of $127.70, indicating a potential upside of 13.26%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Rhythm Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52

97.0% of Incyte shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 16.2% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Incyte had 8 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 8 mentions for Incyte and 0 mentions for Rhythm Pharmaceuticals. Incyte's average media sentiment score of 0.40 beat Rhythm Pharmaceuticals' score of 0.00 indicating that Incyte is being referred to more favorably in the news media.

Company	Overall Sentiment
Rhythm Pharmaceuticals	Neutral
Incyte	Neutral

Incyte has a net margin of 27.71% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Incyte's return on equity of 29.93% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Incyte	27.71%	29.93%	22.88%

Incyte has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$239.92M	25.61	-$196.54M	-$3.11	N/A
Incyte	$5.14B	4.45	$1.29B	$7.85	14.36

Summary

Incyte beats Rhythm Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

BioNTech has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 2.01, indicating that its stock price is 101% more volatile than the broader market.

In the previous week, BioNTech had 22 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 22 mentions for BioNTech and 0 mentions for Rhythm Pharmaceuticals. BioNTech's average media sentiment score of 0.46 beat Rhythm Pharmaceuticals' score of 0.00 indicating that BioNTech is being referred to more favorably in the media.

Company	Overall Sentiment
BioNTech	Neutral
Rhythm Pharmaceuticals	Neutral

BioNTech has a net margin of -63.54% compared to Rhythm Pharmaceuticals' net margin of -85.59%. BioNTech's return on equity of -6.86% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

Rhythm Pharmaceuticals has lower revenue, but higher earnings than BioNTech. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.17	-$1.29B	-$7.83	N/A
Rhythm Pharmaceuticals	$239.92M	25.61	-$196.54M	-$3.11	N/A

BioNTech presently has a consensus target price of $125.69, suggesting a potential upside of 36.53%. Rhythm Pharmaceuticals has a consensus target price of $140.89, suggesting a potential upside of 57.17%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	6 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.65
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76

15.5% of BioNTech shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

BioNTech beats Rhythm Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

In the previous week, Genmab A/S had 23 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 23 mentions for Genmab A/S and 0 mentions for Rhythm Pharmaceuticals. Genmab A/S's average media sentiment score of 0.25 beat Rhythm Pharmaceuticals' score of 0.00 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Overall Sentiment
Genmab A/S	Neutral
Rhythm Pharmaceuticals	Neutral

Genmab A/S has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	6.05	$963M	$1.27	28.39
Rhythm Pharmaceuticals	$239.92M	25.61	-$196.54M	-$3.11	N/A

Genmab A/S has a net margin of 19.08% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Genmab A/S's return on equity of 14.89% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

Genmab A/S has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 2.01, suggesting that its share price is 101% more volatile than the broader market.

Genmab A/S presently has a consensus price target of $42.50, suggesting a potential upside of 17.89%. Rhythm Pharmaceuticals has a consensus price target of $140.89, suggesting a potential upside of 57.17%. Given Rhythm Pharmaceuticals' higher probable upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76

7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Genmab A/S beats Rhythm Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

Get Rhythm Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RYTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RYTM vs. The Competition

Export

Metric	Rhythm Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.22B	$3.89B	$7.20B	$13.28B
Dividend Yield	N/A	3.65%	2.53%	16.36%
P/E Ratio	-29.19	13.55	274.48	26.17
Price / Sales	25.93	1,192.07	585.26	80.91
Price / Cash	N/A	117.60	76.82	53.72
Price / Book	43.64	17.17	11.21	6.34
Net Income	-$196.54M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-2.21%	-1.22%	-0.85%	-1.38%
1 Month Performance	-10.17%	-9.73%	-5.44%	-4.30%
1 Year Performance	-9.41%	9.99%	4.34%	-0.35%

Rhythm Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RYTM Rhythm Pharmaceuticals	3.1313 of 5 stars	$90.78 +1.3%	$140.89 +55.2%	-10.6%	$6.22B	$239.92M	N/A	414	Analyst Forecast
ROIV Roivant Sciences	3.2551 of 5 stars	$36.98 +3.3%	$45.64 +23.4%	+113.4%	$25.86B	$8.26M	N/A	721
INSM Insmed	3.0846 of 5 stars	$117.67 -0.1%	$201.87 +71.6%	-37.9%	$25.73B	$606.42M	N/A	1,664	Analyst Forecast
INCY Incyte	3.9013 of 5 stars	$124.82 +0.8%	$124.80 0.0%	+32.1%	$25.11B	$5.14B	15.90	2,844	Analyst Forecast
BNTX BioNTech	3.9632 of 5 stars	$99.08 +0.6%	$126.00 +27.2%	-13.4%	$24.91B	$3.25B	N/A	7,807	Trending News Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RYTM) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rhythm Pharmaceuticals (RYTM) Competitors

RYTM vs. ROIV, INSM, INCY, BNTX, and GMAB

How does Rhythm Pharmaceuticals compare to Roivant Sciences?

Summary

How does Rhythm Pharmaceuticals compare to Insmed?

Summary

How does Rhythm Pharmaceuticals compare to Incyte?

Summary

How does Rhythm Pharmaceuticals compare to BioNTech?

Summary

How does Rhythm Pharmaceuticals compare to Genmab A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYTM vs. The Competition

Rhythm Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rhythm Pharmaceuticals (RYTM) Competitors

RYTM vs. ROIV, INSM, INCY, BNTX, and GMAB

How does Rhythm Pharmaceuticals compare to Roivant Sciences?

Do analysts rate RYTM or ROIV?

Does the media refer more to RYTM or ROIV?

Do insiders & institutionals believe in RYTM or ROIV?

Which has stronger earnings & valuation, RYTM or ROIV?

Which has more volatility and risk, RYTM or ROIV?

Is RYTM or ROIV more profitable?

Summary

How does Rhythm Pharmaceuticals compare to Insmed?

Is INSM or RYTM more profitable?

Does the media prefer INSM or RYTM?

Which has better earnings & valuation, INSM or RYTM?

Do analysts rate INSM or RYTM?

Which has more risk & volatility, INSM or RYTM?

Summary

How does Rhythm Pharmaceuticals compare to Incyte?

Which has more risk & volatility, RYTM or INCY?

Do analysts rate RYTM or INCY?

Do insiders & institutionals believe in RYTM or INCY?

Does the media prefer RYTM or INCY?

Is RYTM or INCY more profitable?

Which has stronger valuation and earnings, RYTM or INCY?

Summary

How does Rhythm Pharmaceuticals compare to BioNTech?

Which has more risk & volatility, BNTX or RYTM?

Does the media favor BNTX or RYTM?

Is BNTX or RYTM more profitable?

Which has preferable valuation & earnings, BNTX or RYTM?

Do analysts recommend BNTX or RYTM?

Do institutionals & insiders hold more shares of BNTX or RYTM?

Summary

How does Rhythm Pharmaceuticals compare to Genmab A/S?

Does the media prefer GMAB or RYTM?

Which has preferable earnings & valuation, GMAB or RYTM?

Is GMAB or RYTM more profitable?

Which has more volatility and risk, GMAB or RYTM?

Do analysts rate GMAB or RYTM?

Do insiders & institutionals hold more shares of GMAB or RYTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYTM vs. The Competition

Rhythm Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools